コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 er was developed to identify inflammation in coronary atheroma.
2 re caused by acute disruption of an unstable coronary atheroma.
3 to decrease the mechanical stability of the coronary atheroma.
4 mulated at ruptured or eroded sites of human coronary atheroma.
5 Lipoprotein(a) is ubiquitous in human coronary atheroma.
6 d intimal medial thickness and the volume of coronary atheroma also can be reduced by LDL cholesterol
8 both vascular and cardiac tissue (including coronary atheroma) and effectively constricts isolated a
9 Pl(A) polymorphisms in relation to extent of coronary atheroma as characterized by angiography and a
10 s were compared with regard to the extent of coronary atheroma at baseline and subsequent change in r
11 vastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) assessed whether ros
12 vastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden [ASTEROID]) was performed at 53
13 A motorized IVUS pullback was used to assess coronary atheroma burden at baseline and after 24 months
14 risk factors with volumetric measurements of coronary atheroma burden in patients with coronary arter
15 omparing the effect of ETC-216 or placebo on coronary atheroma burden measured by intravascular ultra
17 Chlamydia pneumoniae has been identified in coronary atheroma, but concomitant serum antibody titers
22 cidence of acute thrombotic complications of coronary atheroma in clinical trials remains unknown.
30 tion of C. pneumoniae from human carotid and coronary atheromas provides additional support for a rol
32 bridization studies using specimens of human coronary atheromas showed expression of IL-8 mRNA in a m
34 serial intravascular ultrasound measures of coronary atheroma volume in patients treated with rosuva
36 mydia pneumoniae and coronary heart disease, coronary atheromas were collected from patients undergoi
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。